Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Presbyopia News
Visus Merges with Tenpoint, Will Advance Brimochol Once-Daily Presbyopia Drop Candidate
Visus Therapeutics and Tenpoint Therapeutics announced Dec. 12 the completion of a merger, with plans to advance Visus’ Brimochol PF, a once-daily eye drop candidate for presbyopia. The combined co...
December 2024 Ophthalmic News Briefs
Dutch company Ophtec announced Nov. 18 that it had gained CE marking for its Artiplus phakic IOL. The company said the lens offered a solution for relatively young presbyopes, typically in their ea...
Ophtec Receives CE Marking for Artiplus Phakic IOL, Targets Young Presbyopes
Dutch company Ophtec announced Nov. 18 that it had gained CE Mark approval for its Artiplus phakic intraocular lens (IOL). The company said the lens offered a solution for relatively young presbyop...
US FDA Accepts NDA For Lenz’ Presbyopia Drop Candidate
Lenz Therapeutics announced Oct. 21 that the US FDA had accepted its new drug application (NDA) for LNZ100, a once-daily, preservative-free eye drop candidate for presbyopia. The FDA assigned a Pre...
Clinical Trial Updates for Ophthalmic Candidates, November 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
November 2024 Ophthalmic News Briefs
Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...
Q3-2024 Ophthalmic Revenue Roundup for AbbVie, Apellis, Glaukos, STAAR, and Lensar
AbbVie, of North Chicago, Illinois, reported Oct. 30 that its Q3-2024 eye care net revenue was $525 million, a 13.5 percent decline (-11.2 percent cc) from $605 million in Q3-2023. Restasis revenue...
US FDA Accepts NDA For Lenz’ Presbyopia Drop Candidate
Lenz Therapeutics announced Oct. 21 that the US FDA had accepted its new drug application (NDA) for LNZ100, a once-daily, preservative-free eye drop candidate for presbyopia. The FDA assigned a Pre...
Ocuphire Pharma Acquires Opus Genetics, Will Operate Under Opus Name
Ocuphire Pharma announced Oct. 22 that it would acquire Opus Genetics in an all-stock transaction. The combined company will operate under the Opus name and will trade on the Nasdaq under the ticke...
Orasis Licenses Qlosi Presbyopia Drops to Optus in Korea for $18 Million, Plus Royalties
Orasis Pharmaceuticals announced Oct. 16 that it had licensed its Qlosi presbyopia drops to Optus Pharmaceuticals for the Korean market. Under the deal, Optus will pay upfront and milestone payment...
Orasis Leads Latest Ophthalmic Deals with $78 Million Financing
Orasis Pharmaceuticals led recent ophthalmic fundraising efforts with $78 million in Series D and structured capital to support the launch of Qlosi drops for presbyopia. Financing announced in the ...
ISOP Meeting Examines Importance of Patient Education and Predictable Outcomes
Patient selection, education, and communication were emphasized throughout the International Society of Presbyopia’s 16th annual conference. The meeting, held Sept. 5 at the Hyatt Regency Hotel in ...
Clinical Trial Updates for Ophthalmic Candidates, September 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
August 2024 Ophthalmic News Briefs
Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application for t...
Lenz Submits NDA to US FDA for LNZ100 Presbyopia Drop Candidate
Lenz Therapeutics announced Aug. 12 that it had submitted a new drug application to the US FDA for LNZ100, a once-daily, preservative-free eye drop candidate for presbyopia. Lenz, of San Diego, Cal...
Beacon Leads Latest Ophthalmic Fundraising with $170 Million in Series B
Beacon Therapeutics led recent ophthalmic fundraising efforts with $170 million in Series B funding to advance its candidates for retinal disease. Financing announced in the past four weeks totaled...
Lenz Reports Positive Topline Phase III Data in Presbyopia, Plans NDA Submission in Mid-2024
Lenz Therapeutics reported April 3 positive topline results from its Phase III CLARITY trials of LNZ100 and LNZ101 for presbyopia. LNZ100 and LNZ101 are preservative free, single-use, once-daily ey...
Lenz Reports Positive Topline Phase III Data in Presbyopia, Plans NDA Submission in Mid-2024
Lenz Therapeutics reported April 3 positive topline results from its Phase III CLARITY trials of LNZ100 and LNZ101 for presbyopia. LNZ100 and LNZ101 are preservative-free, single-use, once-daily ey...
February 2024 Ophthalmic News Briefs
Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...
Ji Xing Leads Latest Ophthalmic Fundraising with $162 Million in Series D Round
China’s Ji Xing Pharmaceuticals led recent ophthalmic fundraising efforts with $162 million in Series D funding to advance its pipeline, which includes five ophthalmic candidates. Financing announc...
FDA Approves 11 Ophthalmic Drug Products in 2023, Rejects Three More
2023 was a busy year for the US FDA in ophthalmology. Among the 11 drug products approved were the first two therapies in the US to treat geographic atrophy; two new drops for dry eye; and a second...
Weekly Surgeon Poll, November 2023
November 2023 Ophthalmic News Briefs
Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis, with offices in the US and Israe...
Lenz Plans Merger with Graphite Bio to Gain Nasdaq Listing, Advance Presbyopia Drop Candidate
Privately held Lenz Therapeutics announced Nov. 15 that it had entered into an agreement to merge with Nasdaq-listed Graphite Bio in an all-stock transaction. The combined company would take the Le...
Ace Vision Group Names Rob Kissling, MD, as Chief Medical Officer
Laser company Ace Vision Group announced Nov. 1 that it had named Rob Kissling, MD, as chief medical officer. Most recently, Kissling served as vice president of clinical and medical affairs at Bau...
US FDA Approves Qlosi from Orasis as Eye Drop Treatment for Presbyopia
Orasis Pharmaceuticals announced Oct. 18 that the US FDA had approved Qlosi (pilocarpine hydrochloride 0.4%), a twice-daily eye drop for presbyopia. The company said it expected Qlosi, a preservati...
ISOP Meeting Analyzes ‘Phacorestoration’ and ‘Presbyopia Botox’
The International Society of Presbyopia highlighted new treatment approaches that come with some interesting names. The conference was held Sept. 7 at the Vienna Marriott Hotel in Vienna, Austria. ...
US FDA Approves Presbyopia Drop Qlosi from Orasis
Orasis Pharmaceuticals announced Oct. 18 that the US FDA had approved Qlosi (pilocarpine hydrochloride 0.4%), a twice-daily eye drop for presbyopia. The company said it expected Qlosi, a preservati...
Q2-2023 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Alimera
AbbVie, of North Chicago, Illinois, reported July 27 that Q2-2023 net revenue for its eye care products totaled $617 million, a 13.9 percent decline from $717 million in Q2-2022. Restasis revenue w...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.